Nov 9 (Reuters) - Nektar Therapeutics :
* NEKTAR AND COLLABORATORS ANNOUNCE PUBLICATION IN BLOOD ADVANCES OF PRECLINICAL DATA DEMONSTRATING NKTR-255, A NOVEL POLYMER-CONJUGATED HUMAN IL-15, IMPROVES EFFICACY OF CD19-TARGETED CAR-T CELL IMMUNOTHERAPY
* NEKTAR THERAPEUTICS - POLYMER-CONJUGATED IL-15 (NKTR-255) INDUCED CD8(+) T CELL AND NATURAL KILLER CELL PROLIFERATION IN VIVO
* NEKTAR THERAPEUTICS - NKTR-255 ENHANCED EFFICACY OF HUMAN CD19 CAR-T CELLS IN A XENOGENEIC LYMPHOMA MODEL
Source text for Eikon: Further company coverage:
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。